Sei Investments Co. Sells 1,481 Shares of Masimo Co. (NASDAQ:MASI)

Sei Investments Co. lessened its position in Masimo Co. (NASDAQ:MASI) by 5.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,601 shares of the medical equipment provider’s stock after selling 1,481 shares during the quarter. Sei Investments Co.’s holdings in Masimo were worth $4,397,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its stake in Masimo by 31.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 60 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 64 shares during the period. Blue Trust Inc. grew its position in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 71 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of Masimo by 0.8% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock valued at $1,622,000 after buying an additional 82 shares during the period. Finally, Thrivent Financial for Lutherans raised its holdings in shares of Masimo by 0.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock valued at $1,728,000 after acquiring an additional 83 shares in the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Masimo

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares of the company’s stock, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 9.70% of the company’s stock.

Masimo Stock Up 2.3 %

MASI stock opened at $171.48 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The firm has a market capitalization of $9.27 billion, a price-to-earnings ratio of 118.26 and a beta of 1.04. The company’s 50 day moving average price is $174.47 and its 200 day moving average price is $162.55.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. On average, equities research analysts anticipate that Masimo Co. will post 4.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MASI has been the subject of a number of analyst reports. Raymond James upped their price objective on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Piper Sandler increased their price target on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, February 26th. Finally, Wells Fargo & Company boosted their price objective on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $194.80.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.